personalized, responsive service and to improve the site, we remember and store information about how you use
Congratulations! You now have unlimited access to all articles from The Medicine Maker.
Complete your profile at your earliest convenience to unlock the rest of your benefits:
relevant and personalised updates about your field
access to White Papers/product profiles
digital magazine subscription
The Medicine Maker
From battling river blindness, to Ebola, to the threat of the coronavirus – March’s cover feature looks at how pharma is standing up to neglected tropical diseases and emerging pathogens. George Chressanthis explains why the coronavirus will have an economic impact on the pharma industry and what companies can do about it; and we catch up with new CEO, Stuart Young, about his change in role and the trends driving the business of clinical trials. In addition, Claudia Zylberberg makes the case for a regulatory framework for cell and gene ancillary materials; while the latest news, views and research, include a new polio vaccine, structure elucidation for natural products, and advice for budding entrepreneurs in the UK. We also sit down with “pharmaceutical nomad” and Chief Executive Officer at Bone Therapeutics, Miguel Forte.